Cowen & Co. Sticks to Its Hold Rating for Unum Therapeutics Inc (UMRX)


In a report released today, Yaron Werber from Cowen & Co. maintained a Hold rating on Unum Therapeutics Inc (UMRX). The company’s shares opened today at $3.30, close to its 52-week low of $3.03.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 13.4% and a 62.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Acceleron Pharma.

Unum Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.

See today’s analyst top recommended stocks >>

Based on Unum Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.61 million. In comparison, last year the company had a GAAP net loss of $6.75 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts